Valthos, Inc.

Based in New York, US, founded in 2024, Valthos, Inc. is a biodefense firm. The company specializes in developing systems to address biodefense challenges but has not reported any significant pivots in its business strategy. The company was co-founded by Tess van Stekelenburg and Kathleen McMahon (CEO as of 2026).

In August 2025, Valthos, Inc. raised USD 27. 29 million in seed funding co-led by Founders Fund, Lux Capital, and Openai Startup Fund Management, with participation from Definition Capital. Valthos specializes in advanced biodefense solutions, focusing on the development and deployment of innovative products aimed at enhancing public health security.

Their core offerings address various biodefense challenges, including pathogen detection, vaccine development, and rapid response systems for biological threats. These solutions are particularly relevant to government and military sectors, serving end users like public health agencies and emergency response teams across North America, Europe, and parts of Asia. Valthos generates revenue through a structured model emphasizing B2B transactions with government agencies and defense organizations. The company engages in contracts often involving multi-year agreements for its biodefense products and services, along with partnerships for co-development of tailored technologies.

Clients typically participate in both direct purchases and long-term subscription agreements, ensuring a continuous revenue stream as they rely on Valthos for essential biodefense capabilities.